Insights on Acute Lymphoblastic Leukemia
Webcast
Webcast

Insights on Acute Lymphoblastic Leukemia

Current State-of-the-Art and Future Strategies

Not a member of My prIME? Join now for instant access.

Listen to the experts in acute lymphoblastic leukemia to get up-to-date information on current and future therapeutic strategies.

Expert faculty presentations with downloadable slides from our satellite symposium held in conjunction with the 22nd Congress of the European Hematology Association in Madrid, Spain

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

1.5 AMA PRA Category 1 Credits™

Release Date

Release Date

Jul 21, 2017

Expiration Date

Jul 21, 2018

Diagnosis and risk assessment of acute lymphoblastic leukemia in 2017
David I. Marks, MBBS, PhD, FRACP, FRCPath

Making the most of induction therapy in acute lymphoblastic leukemia
Dieter Hoelzer, MD, PhD

Minimal residual disease and risk-adapted post-remission therapy
Robin Foà, MD

New strategies for relapsed/refractory acute lymphoblastic leukemia
Max S. Topp, MD

FACULTY

  • Robin Foà, MDUniversity of Rome
    Rome, Italy
  • Dieter Hoelzer, MD, PhDOnkologikum Frankfurt am Museumsufer
    Frankfurt, Germany
  • David I. Marks, MBBS, PhD, FRACP, FRCPathUniversity Hospitals Bristol NHS Foundation Trust
    Bristol, United Kingdom
  • Max S. Topp, MDUniversity of Würzburg
    Würzburg, Germany

This educational activity is designed for hematologists, medical oncologists, and other healthcare providers involved in the management of patients with acute lymphoblastic leukemia.

After successful completion of this educational activity, participants should be able to:

  • Distinguish standard-risk versus high-risk patients with acute lymphoblastic leukemia based upon disease-specific and patient-specific factors
  • Integrate age-adapted protocols into initial therapy of patients with acute lymphoblastic leukemia
  • Identify patients with acute lymphoblastic leukemia who may avoid allogeneic stem cell transplant in first remission based upon minimal residual disease status and post-induction risk
  • Describe novel therapies demonstrating activity in relapsed/refractory acute lymphoblastic leukemia

This educational activity is supported by a grant from Shire.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Insights on Acute Lymphoblastic Leukemia - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Foà has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Gilead, Janssen, Novartis, Roche, and Sandoz. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hoelzer has disclosed that he has received consulting fees from Amgen and Celgene. He has also received fees for non-CME services from Amgen, Jazz Pharmaceuticals, Medac Pharma, and Shire. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Marks has disclosed that he has received consulting fees from Amgen and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Topp has disclosed that he has received consulting fees from Amgen and Regeneron. He has also disclosed that he has performed contracted research for Amgen, Affimed, Boehringer Ingelheim, Gilead, Macrogenics, Pfizer, Regeneron, Roche, and Servier. He has also disclosed receipt of fees for non-CME services from Amgen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.